Skip to main content

NRX Pharmaceuticals, Inc.

corporate_fare Company Profile

NRX Pharmaceuticals, Inc.

NRXP·NASDAQ·Life Sciences·CIK 0001719406

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops and will distribute new treatments for central nervous system disorders, including suicidal depression, chronic pain, post-traumatic stress disorder (PTSD), and schizophrenia, through its wholly-owned subsidiary, NeuroRx, Inc. NRx is also the founder and majority owner of HOPE Therapeutics, Inc., a medical services company offering interventional psychiatry care for patients with treatment-resistant depression and PTSD, utilizing neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy. The company's current drug development focuses on drugs that enhance neuroplasticity by modulating the N-methyl-D-aspartate (NMDA) receptor. NRx has three lead drug candidates: NRX-100, a preservative-free formulation of ketamine for intravenous infusion; KETAFREE™, a generic preservative-free formulation of ketamine; and NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone. An Abbreviated New Drug Application (ANDA) for KETAFREE™ was filed, with priority review requested in September 2025. The FDA approved the suitability of NRx's proposed strength. On November 6, 2025, the Company received a communication from the FDA with no significant deficiencies identified in the revised filing. On March 15, 2026, the Company received FDA's preliminary determination of no deficiency in the bioequivalence of KETAFREE™ to KETALAR®, the Reference Listed Drug. The company plans to initiate commercial sales of KETAFREE™ with FDA approval in Q3 2026. NRx has submitted a citizen petition to remove benzethonium chloride from commercial ketamine presentations. The company has completed manufacturing steps, including three reference batches of KETAFREE™, and demonstrated room temperature shelf stability anticipated to support a three-year shelf life at launch.

NRX Pharmaceuticals, Inc. (NASDAQ:NRXP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 43 items for NRXP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for NRXP spans 10-Q, 8-K, 424B5.

Recent high-impact activity:

  • NRx Posts $2.2M Q3 Loss as First Ketamine Launch Begins
  • NRx 10-Q: Q3 Loss Narrows to $2.2M, But Going-Concern Doubt Persists
  • FDA Approves NRx's Preservative-Free Ketamine Weeks Ahead of Goal Date
  • FDA Flags Only Minor Label Changes on NRx Ketamine ANDA Ahead of Nov. 10 Decision
  • NRx Defense Systems Signs $11.2M DARPA Prime Contract for SPARC-TMS Trial

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.23M
Net Income
-$28.62M
Op. Cash Flow
-$14.11M
Gross Profit
$720K
Operating Income
-$16.22M
Cash & Equivalents
$7.8M
Debt / Equity
0.00×
Net Margin
-23.36×
Shares Outstanding
31.73M sh
Source: 10-K · filed 2026-03-23 · accession 0001437749-26-009418

Short Interest & Short Volume

4.56 days to cover

FINRA reported short interest of 10,462,226 shares in NRXP as of the October 30, 2026 settlement, a 5.2% increase from the prior period — about 4.6 days to cover at its recent average daily volume. On November 20, 2026, 41.4% of NRXP volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)10,462,226 shares as of October 30, 2026
Change vs prior period▲ 5.2%
Days to cover4.56 at avg daily volume of 2,293,911
Daily short volume (FINRA facilities)41.4% of 1,005,667 shares on November 20, 2026
5-day average short volume48.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for NRXP, detected from its recent SEC filings · based on capital-structure filings through 2026-06-04.

1 recent capital raise

Public Offering Priced · Significant Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with N →
$2.23 +3.69% today
52-week range · as of 2026-11-16 $1.62 – $5.05
Market cap
$95.31M
Volume
1.5M (0.9× avg)
3-mo avg 1.6M
Live data · 2026-11-21 13:25 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NRXP - Latest Insights

NRXP
Nov 17, 2026, 7:18 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.10
Real-time Price: $2.23 info
Change: +$0.1293 (+6%) info
Market Cap: $95.305M info
NRXP
Nov 16, 2026, 4:32 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.88
Real-time Price: $2.23 info
Change: -$0.6507 (-23%) info
Market Cap: $95.305M info
NRXP
Oct 30, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $2.98
Real-time Price: $2.23 info
Change: -$0.7505 (-25%) info
Market Cap: $95.305M info
NRXP
Oct 15, 2026, 8:27 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.55
Real-time Price: $2.23 info
Change: -$0.3207 (-13%) info
Market Cap: $95.305M info
NRXP
Oct 05, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.86
Real-time Price: $2.23 info
Change: -$0.6307 (-22%) info
Market Cap: $95.305M info
NRXP
Sep 30, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.98
Real-time Price: $2.23 info
Change: -$0.7552 (-25%) info
Market Cap: $95.305M info
NRXP
Sep 15, 2026, 9:17 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.35
Real-time Price: $2.23 info
Change: -$1.12 (-33%) info
Market Cap: $95.305M info
NRXP
Sep 14, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.42
Real-time Price: $2.23 info
Change: -$1.19 (-35%) info
Market Cap: $95.305M info
NRXP
Sep 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.40
Real-time Price: $2.23 info
Change: -$1.17 (-34%) info
Market Cap: $95.305M info
NRXP
Aug 17, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.19
Real-time Price: $2.23 info
Change: -$0.9607 (-30%) info
Market Cap: $95.305M info
NRXP
Aug 17, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.25
Real-time Price: $2.23 info
Change: -$1.02 (-31%) info
Market Cap: $95.305M info
NRXP
Aug 14, 2026, 4:32 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.17
Real-time Price: $2.23 info
Change: -$0.9407 (-30%) info
Market Cap: $95.305M info
NRXP
Aug 07, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.18
Real-time Price: $2.23 info
Change: -$0.9507 (-30%) info
Market Cap: $95.305M info
NRXP
Jul 22, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.43
Real-time Price: $2.23 info
Change: -$2.20 (-50%) info
Market Cap: $95.305M info
NRXP
Jun 25, 2026, 5:12 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.62
Real-time Price: $2.23 info
Change: -$1.39 (-38%) info
Market Cap: $95.305M info
NRXP
Jun 24, 2026, 1:23 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $3.71
Real-time Price: $2.23 info
Change: -$1.48 (-40%) info
Market Cap: $95.305M info
NRXP
Jun 22, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.98
Real-time Price: $2.23 info
Change: -$1.75 (-44%) info
Market Cap: $95.305M info
NRXP
Jun 04, 2026, 5:20 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.00
Real-time Price: $2.23 info
Change: -$1.77 (-44%) info
Market Cap: $95.305M info
NRXP
Jun 04, 2026, 5:12 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.00
Real-time Price: $2.23 info
Change: -$1.77 (-44%) info
Market Cap: $95.305M info
NRXP
Jun 03, 2026, 4:11 PM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $4.00
Real-time Price: $2.23 info
Change: -$1.77 (-44%) info
Market Cap: $95.305M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets